Nymox Pharmaceutical

Nymox Pharmaceutical Corporation (Nymox) is a biopharmaceutical company.

Nymox Pharmaceutical Corporation (Nymox) is a biopharmaceutical company. The Company focuses on developing NX-1207, a treatment for benign prostatic hyperplasia (BPH) which is in Phase III trials in the United States. The Company has research and development (R&D) pipeline of products in development for the treatment of such conditions and diseases as enlarged prostate (benign prostatic hyperplasia (BPH)), Alzheimer’s disease (AD), E. coli O157:H7 contamination of food and drink products, and bacterial infections and for the diagnosis of AD and other indications. The Company is in the preclinical stage of developing therapeutic products for oncological indications based on technology licensed from the Massachusetts General Hospital. Nymox has a number of diagnostic markers and technologies, including a patented platform for point-of-care testing, and has tests utilizing these technologies in the early stages of development.